Cargando…
Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets
Platelet transfusion is a common clinical approach to providing platelets to patients suffering from thrombocytopenia or other ailments that require an additional platelet source. However, a stable supply of platelet products is challenged by aging societies, pandemics, and other factors. Many group...
Autores principales: | Chen, Si Jing, Sugimoto, Naoshi, Eto, Koji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792917/ https://www.ncbi.nlm.nih.gov/pubmed/36574167 http://dx.doi.org/10.1007/s12185-022-03512-8 |
Ejemplares similares
-
Ex Vivo Production of Platelets From iPSCs: The iPLAT1 Study and Beyond
por: Sugimoto, Naoshi, et al.
Publicado: (2023) -
Generation and manipulation of human iPSC-derived platelets
por: Sugimoto, Naoshi, et al.
Publicado: (2021) -
Ex vivo generation of platelet products from human iPS cells
por: Nakamura, Sou, et al.
Publicado: (2020) -
Production and nonclinical evaluation of an autologous iPSC–derived platelet product for the iPLAT1 clinical trial
por: Sugimoto, Naoshi, et al.
Publicado: (2022) -
Manipulating megakaryocytes to manufacture platelets ex vivo
por: Karagiannis, P, et al.
Publicado: (2015)